DASA showcases tomorrow's technology today

Top innovators pitched their businesses and novel technological ideas to investors at an event by the Defence and Security Accelerator (DASA).

More than 45 investors attended the virtual Investment Showcase earlier this month with 14 companies presenting their innovative business opportunities and associated technologies that have the potential to offer better performance and increased capability for defence and national security - as well as offering multiple uses across other sectors.

The companies were split by technology area, to allow investors to easily identify those sessions of particular interest.

The innovations on display ranged from different software that tackles fake news and reduces harmful content to innocent audiences; a medical point of care innovation that provides a diagnostic answer in ten minutes on a patient's need for antibiotics; to drone software that could transform the signal denied autonomy aspect of the drone market; and others.

Categories showcased were:

  • Cyber, Analysis and Training Software
  • Medical Software and Scanning
  • Advanced Materials
  • Drones and Drone Software

An invited audience of investors saw each company present their business opportunity and growth plans.

All companies presenting have previously received either defence or security funding via DASA.

DASA offers our funded companies the opportunity to access business mentoring and finance advice, with pitch training a core training element.

DASA is resolute in its support of UK companies to help them reach the next level of development and funding necessary to take their innovation into the market place.

Investors who are interested in more details about UK innovations are welcome to

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.